225 related articles for article (PubMed ID: 25633239)
1. Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application.
Wolzt M; Gouya G; Sator M; Hemetsberger T; Irps C; Rettenbacher M; Vcelar B
Eur J Drug Metab Pharmacokinet; 2016 Jun; 41(3):259-65. PubMed ID: 25633239
[TBL] [Abstract][Full Text] [Related]
2. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
3. In-vivo biological activity and glycosylation analysis of a biosimilar recombinant human follicle-stimulating hormone product (Bemfola) compared with its reference medicinal product (GONAL-f).
Mastrangeli R; Satwekar A; Cutillo F; Ciampolillo C; Palinsky W; Longobardi S
PLoS One; 2017; 12(9):e0184139. PubMed ID: 28880909
[TBL] [Abstract][Full Text] [Related]
4. A multi-centre phase 3 study comparing efficacy and safety of Bemfola(®) versus Gonal-f(®) in women undergoing ovarian stimulation for IVF.
Rettenbacher M; Andersen AN; Garcia-Velasco JA; Sator M; Barri P; Lindenberg S; van der Ven K; Khalaf Y; Bentin-Ley U; Obruca A; Tews G; Schenk M; Strowitzki T; Narvekar N; Sator K; Imthurn B
Reprod Biomed Online; 2015 May; 30(5):504-13. PubMed ID: 25735918
[TBL] [Abstract][Full Text] [Related]
5. Phase I, two-way, crossover study to demonstrate bioequivalence and to compare safety and tolerability of single-dose XM17 vs Gonal-f® in healthy women after follicle-stimulating hormone downregulation.
Lammerich A; Mueller A; Bias P
Reprod Biol Endocrinol; 2015 Dec; 13():130. PubMed ID: 26621118
[TBL] [Abstract][Full Text] [Related]
6. Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART).
Strowitzki T; Kuczynski W; Mueller A; Bias P
Reprod Biol Endocrinol; 2016 Jan; 14():1. PubMed ID: 26733057
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety, and immunogenicity of a biosimilar recombinant human follicle-stimulating hormone (Folitime®) vs. Gonal-f® in women undergoing ovarian stimulation for IVF: A randomized, multicenter, evaluator-blinded, non-inferiority study.
Pasqualini A; Ruhlmann C; Botti GA; Estofán DE; Pasqualini S; Inciarte F; Ruhlmann F; Lopez C; Palena C; Klimovsky E; Federico A; Gonzalez E; Cordeiro L; Lago N
JBRA Assist Reprod; 2021 Oct; 25(4):524-532. PubMed ID: 34338481
[TBL] [Abstract][Full Text] [Related]
8. Bioequivalence of recombinant human FSH and recombinant human LH in a fixed 2:1 combination: two phase I, randomised, crossover studies.
Picard M; Rossier C; Papasouliotis O; Lugan I
Curr Med Res Opin; 2008 Apr; 24(4):1199-208. PubMed ID: 18348746
[TBL] [Abstract][Full Text] [Related]
9. Bemfola
Foxon G; Mitchell P; Turner N; McConnell A; Kendrew H; Jenkins J
Hum Fertil (Camb); 2018 Dec; 21(4):275-280. PubMed ID: 28549400
[TBL] [Abstract][Full Text] [Related]
10. Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study.
Kaplan S; Levy-Toledano R; Davies M; Roy D; Howles CM; Lass A
Front Endocrinol (Lausanne); 2021; 12():632674. PubMed ID: 33815290
[TBL] [Abstract][Full Text] [Related]
11. Comparison of recombinant human FSH biosimilar QL1012 with Gonal-f® for ovarian stimulation: a phase-three trial.
Hu L; Lv J; Ma Q; Chen X; Wang X; Liang X; Xu D; Li Y; Huang Y; Hu L; Deng X; Wei J; Zhou F; Zhang S; Wang J; Ma F; Sun Y
Reprod Biomed Online; 2023 Mar; 46(3):511-518. PubMed ID: 36621365
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy and safety of a new recombinant human follicle-stimulating hormone (DA-3801) with follitropin-alpha (Gonal-F) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology.
Moon SY; Choi YS; Ku SY; Kim SH; Choi YM; Kang IS; Kim CH
J Obstet Gynaecol Res; 2007 Jun; 33(3):305-15. PubMed ID: 17578360
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study.
Strowitzki T; Kuczynski W; Mueller A; Bias P
Reprod Biol Endocrinol; 2016 Jun; 14(1):31. PubMed ID: 27287439
[TBL] [Abstract][Full Text] [Related]
14. A comparative, observational study evaluating dosing characteristics and ovarian response using the recombinant human follicle-stimulating hormone pen injector with small-dose dial in assisted reproductive technologies treatment in Asia: IMPROVE study.
Choi BC; Zhou C; Ye H; Sun Y; Zhong Y; Gong F; Sini I; Abramova N; Longobardi S; Hickey M; D'Hooghe T
Reprod Biol Endocrinol; 2022 Jan; 20(1):15. PubMed ID: 35039049
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of recombinant human follicle stimulating hormone after intravenous, intramuscular, and subcutaneous administration in monkeys, and comparison with intravenous administration of urinary follicle stimulating hormone.
Porchet HC; Le Cotonnec JY; Canali S; Zanolo G
Drug Metab Dispos; 1993; 21(1):144-50. PubMed ID: 8095209
[TBL] [Abstract][Full Text] [Related]
16. A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose.
Barrière P; Hamamah S; Arbo E; Avril C; Salle B; Pouly JL; Jenkins J;
J Gynecol Obstet Hum Reprod; 2023 Jan; 52(1):102510. PubMed ID: 36403900
[TBL] [Abstract][Full Text] [Related]
17. Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap
Winstel R; Wieland J; Gertz B; Mueller A; Allgaier H
Drugs R D; 2017 Jun; 17(2):305-312. PubMed ID: 28386738
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of the use and handling errors of currently available recombinant human follicle-stimulating hormone pen injectors by women with infertility and fertility nurses.
Longobardi S; Seidler A; Martins J; Beckers F; MacGillivray W; D'Hooghe T
Expert Opin Drug Deliv; 2019 Sep; 16(9):1003-1014. PubMed ID: 31411099
[No Abstract] [Full Text] [Related]
19. The population pharmacokinetics of recombinant- and urinary-human follicle stimulating hormone in women.
Karlsson MO; Wade JR; Loumaye E; Munafo A
Br J Clin Pharmacol; 1998 Jan; 45(1):13-20. PubMed ID: 9489588
[TBL] [Abstract][Full Text] [Related]
20. The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review.
Velthuis E; Hubbard J; Longobardi S; D'Hooghe T
Adv Ther; 2020 Dec; 37(12):4831-4847. PubMed ID: 33058045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
